Daclatasvir Dihydrochloride
Deskripsyon
Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) se yon pisan ak oralman aktif.HCV NS5A pwoteyininhibiteur akEC50s ranje 9-146 pM pouplizyè jenotip replikon HCV.Daclatasvir dihydrochloride se tou yonòganik anyon transpòte polipèptid 1B (OATP1B)epiOATP1B3inhibiteur akIC50s nan 1.5 µM ak 3.27 µM, respektivman.
IC50& Sib
EC50: 50 pM (HCV replicon jenotip 1a), 9 pM (HCV replicon jenotip 1b), 71 pM (HCV replicon jenotip 2a), 146 pM (HCV replicon jenotip 3a), 12 pM (HCV replicon jenotip 4a) ak HCV replicon jenotip 5a)[1]
Kd: 8 nM (NS5A33-202) ak 210 nM (NS5A26-202)[2]
IC50: 1.5 µM (OATP1B) ak 3.27 µM (OATP1B3)[3]
In vitro
Daclatasvir (BMS-790052) demontre aktivite inhibitor ki pisan nan direksyon pou tout jenotip yo teste, ak EC.50valè ki sòti nan 9 pM a 146 pM.Daclatasvir inibit HCV replicon jenotip 1a, 1b, 2a, 3a, 4a ak 5a ak EC50valè 50 pM, 9 pM, 71 pM, 146 pM, 12 pM ak 33 pM, respektivman.Daclatasvir se yon inibitè ki pisan nan viris enfektye JFH-1 jenotip 2a ki repwodui nan kilti selilè (EC).50= 28 pM)[1].Daclatasvir (BMS-790052) mare byen sere nan NS5A33-202 ak NS5A26-202 ak K.ds nan 8 nM ak 210 nM, respektivman[2].
Depo
| Poud | -20°C | 3 zan |
| 4°C | 2 zan | |
| Nan sòlvan | -80°C | 6 mwa |
| -20°C | 1 mwa |
Esè klinik
| Nimewo NCT | Sponsor | Kondisyon | Dat Kòmanse | Faz |
| NCT03369327 | Tehran University of Medical Sciences|RojanPharma Pharmaceutical Company | Enfeksyon Viris Epatit C, Repons a Terapi |Viris Iminodefisyans Imèn | 1ye janvye 2017 | Faz 3 |
| NCT03485846 | R-Pharm|Almedis | Epatit C kwonik jenotip 1b | 27 novanm 2017 | Faz 2 |
| NCT01016912 | Bristol-Myers Squibb | Enfeksyon epatit C | Desanm 2009 | Faz 2 |
| NCT01629732 | Bristol-Myers Squibb | Viris Epatit C | Mas 2013 | Faz 2 |
| NCT01497834 | Bristol-Myers Squibb | Epatit C | Janvye 2012 | Faz 3 |
| NCT01973049 | Bristol-Myers Squibb | Epatit C | Desanm 2013 | Faz 3 |
| NCT00663208 | Bristol-Myers Squibb | Epatit C kwonik | Me 2008 | Faz 2 |
| NCT02576314 | Sant rechèch limanite ak sante|Beijing 302 Lopital | Enfeksyon kwonik epatit C | Me 2015 | Faz 3 |
| NCT02756936 | Genuine Research Center, peyi Lejip|Zeta Pharmaceutical Industries | An sante | Fevriye 2016 | Faz 1 |
| NCT02771405 | National Hepatology & Tropical Medicine Research Institute|Cairo University | Epatit C, Kwonik|Kansòm epatoselilè | Mas 2016 | Faz 3 |
| NCT03706898 | Viriom | VIH-1-enfeksyon|Defisyans Epatik | 1ye oktòb 2018 | Faz 1 |
| NCT02319031 | Bristol-Myers Squibb | Epatit C | Fevriye 2015 | Faz 3 |
| NCT02124044 | National Institutes of Health Clinical Center (CC)|Enstiti Nasyonal pou Alèji ak Maladi Enfektye (NIAID)|Bristol-Myers Squibb | VIH-HCV | Fevriye 2014 | Faz 2 |
| NCT02551861 | Bristol-Myers Squibb | Epatit C | Desanm 2015 | Faz 2 |
| NCT00859053 | Bristol-Myers Squibb | Ensifizans epatik | Mas 2009 | Faz 1 |
| NCT01257204 | Bristol-Myers Squibb | Viris Epatit C | Desanm 2010 | Faz 2 |
| NCT03063879 | Tehran University of Medical Sciences|Ahvaz Jundishapur University of Medical Sciences|Shiraz University of Medical Sciences|University of Medical Sciences Hamadan | Epatit C, Kwonik | Ensifizans Renal Kwonik | 1ye avril 2017 | Faz 4 |
| NCT01017575 | Bristol-Myers Squibb | Enfeksyon epatit C | Desanm 2009 | Faz 2 |
| NCT02865369 | Sang Gyune Kim|Seoul National University Boramae Hospital|Severance Hospital|Inha University Hospital|Korea University|Gachon University Gil Medical Center|Hanyang University Seoul Hospital|Ewha Womans University Mokdong Hospital|Bristol-Myers Squibb|Soonchunhyang University Hospital | Epatit C kwonik | Septanm 2016 |
|
| NCT04070235 | Nanjing Sanhome famasetik, co, Ltd. | Epatit C, kwonik | 29 mas 2019 | Faz 2| Faz 3 |
| NCT03487848 | Bristol-Myers Squibb | Epatit C|Epatit kwonik | 18 me 2018 | Faz 2 |
| NCT00904059 | Bristol-Myers Squibb | Epatit C | Me 2009 | Faz 1 |
| NCT02107365 | Enstiti nasyonal franse pou sante ak rechèch medikal-Ajans nasyonal franse pou rechèch sou SIDA ak epatit viral (Inserm-ANRS)|Bristol-Myers Squibb | Epatit C Viris Jenotip 4 Enfeksyon | Novanm 2013 | Faz 2 |
| NCT02397395 | Janssen R&D Iland | Enfimite Renal|Maladi Renal Etap Fen | Me 2015 | Faz 2 |
| NCT03169348 | Inivèsite Assiut | Epatit C | 1ye novanm 2017 | Pa aplikab |
| NCT02323594 | Bristol-Myers Squibb | Enfeksyon epatit C | Desanm 2014 | Faz 1 |
| NCT03537196 | Enstiti nasyonal franse pou sante ak rechèch medikal-Ajans nasyonal franse pou rechèch sou SIDA ak epatit viral (Inserm-ANRS) | Epatit C|Itilize dwòg|Epatit C viral | 13 novanm 2018 | Faz 4 |
| NCT02103569 | Bristol-Myers Squibb | Epatit C | Avril 2014 | Faz 1 |
| NCT02772744 | Zagazig University|Kairo University | Epatit C | 1ye novanm 2017 |
|
| NCT01718158 | Bristol-Myers Squibb | Epatit C | Janvye 2013 | Faz 3 |
| NCT02496078 | Bristol-Myers Squibb | Epatit C | Out 2015 | Faz 3 |
| NCT01425970 | Bristol-Myers Squibb | Epatit C | Me 2012 | Faz 2 |
| NCT01471574 | Bristol-Myers Squibb | Epatit C, jenotip 1 | Desanm 2011 | Faz 3 |
| NCT01573351 | Bristol-Myers Squibb | Viris Epatit C | Me 2012 | Faz 3 |
| NCT01938625 | Janssen R&D Iland | Epatit C, kwonik | 12 desanm 2013 | Faz 2 |
| NCT01492426 | Bristol-Myers Squibb | Epatit C | Janvye 2012 | Faz 3 |
| NCT03480932 | Johns Hopkins Bloomberg School of Public Health|National Institute on Drug Abuse (NIDA)|YR Gaitonde Center for AIDS Research and Education | Epatit C, kwonik | 2 fevriye 2018 | Faz 2| Faz 3 |
| NCT03163849 | Inivèsite Assiut | Epatit kwonik c | 1ye septanm 2019 | Faz 3 |
| NCT01581203 | Bristol-Myers Squibb | Viris Epatit C | Me 2012 | Faz 3 |
| NCT01492504 | Bristol-Myers Squibb | Epatit C | 7 fevriye 2012 |
|
| NCT03686722 | Mohamed Raslan|Ain Shams University|Drog Research Center, Cairo, Egypt | Dyabèt Melito, Kalite 2|Epatit C|Entèaksyon Medikaman | 9 septanm 2017 | Faz 1 |
| NCT02262728 | Janssen Research & Development, LLC | Epatit C, kwonik | 30 septanm 2014 | Faz 2 |
| NCT02349048 | Janssen Research & Development, LLC | Viris Epatit C | Janvye 2015 | Faz 2 |
| NCT03882307 | Inivèsite Assiut | Epatit C, kwonik | Me 2020 | Faz bonè 1 |
| NCT02758509 | Parc de Salut Mar | Epatit C kwonik | Siwoz | 1ye janvye 2010 |
|
| NCT01795911 | Bristol-Myers Squibb | Epatit C | Mas 2013 | Faz 2 |
| NCT03549832 | Assiut University|Sohag University|South Valley University | Koinfeksyon HCV | 1ye janvye 2018 | Pa aplikab |
| NCT02161939 | Bristol-Myers Squibb | Epatit C kwonik |
| |
| NCT01309932 | Bristol-Myers Squibb | Epatit C | Mas 2011 | Faz 2 |
| NCT01995266 | Bristol-Myers Squibb | Epatit C | 28 fevriye 2014 | Faz 3 |
| NCT02640157 | AbbVie | Epatit C Kwonik|Viris Epatit C|Jenotip 3 Viris Epatit C | Desanm 2015 | Faz 3 |
| NCT02032875 | Bristol-Myers Squibb | Epatit C | Mas 2014 | Faz 3 |
| NCT02624063 | Inivèsite Federal São Paulo | Epatit C, kwonik | Desanm 2015 | Faz 4 |
| NCT00546715 | Bristol-Myers Squibb | Epatit C kwonik | Novanm 2007 | Faz 1 | Faz 2 |
| NCT01718145 | Bristol-Myers Squibb | Enfeksyon Viris Epatit C | Novanm 2012 | Faz 3 |
| NCT01616524 | Bristol-Myers Squibb | Viris Epatit C (HCV) | Jiyè 2012 | Faz 3 |
| NCT02032901 | Bristol-Myers Squibb | Epatit C | Janvye 2014 | Faz 3 |
| NCT03540212 | Inivèsite Ain Shams | Enfeksyon kwonik HCV | 10 desanm 2017 | Faz 2| Faz 3 |
| NCT02097966 | Bristol-Myers Squibb | Epatit C kwonik |
| |
| NCT02596880 | Teheran University of Medical Sciences | Epatit C | Siwoz | Septanm 2015 | Faz 3 |
| NCT04019717 | Atea Pharmaceuticals, Inc. | Epatit C|Epatit C, Kwonik|Epatit C kwonik|Enfeksyon Viris Epatit C|Enfeksyon HCV | 20 jen 2019 | Faz 2 |
| NCT02992457 | Tanta Inivèsite | Epatit C | Janvye 2015 | Faz 4 |
| NCT03547895 | Inivèsite Zagazig | Siwoz dekonpanse | 1ye jen 2015 | Pa aplikab |
| NCT03004625 | Kaohsiung Medical University Chung-Ho Memorial Hospital|Chang Gung Memorial Hospital|National Taiwan University Hospital|Taipei Veterans General Hospital, Taiwan|China Medical University Hospital|National Cheng-Kung University Hospital | Epatit C | Novanm 2016 | Faz 3 |
| NCT01051414 | Bristol-Myers Squibb | Enfeksyon epatit C | Avril 2010 | Faz 2 |
| NCT02309450 | Enstiti nasyonal franse pou sante ak rechèch medikal-Ajans nasyonal franse pou rechèch sou SIDA ak epatit viral (Inserm-ANRS)|Bristol-Myers Squibb | Epatit C Viris Jenotip 4 Enfeksyon | Desanm 2014 | Faz 2 |
| NCT01628692 | Bristol-Myers Squibb|Janssen Research & Development, LLC | Viris Epatit C | Jiyè 2012 | Faz 2 |
| NCT03186313 | Lopital fwa moun peyi Lejip|Wadi El Nil Hospital | Epatit C | Septanm 2016 | Faz 3 |
| NCT03063723 | Twazyèm Lopital Afilye, Inivèsite Sun Yat-Sen | Epatit C kwonik (Trouble) | 1ye janvye 2016 |
|
| NCT00983957 | Bristol-Myers Squibb | Epatit C kwonik | Oktòb 2009 | Faz 1 |
| NCT01725542 | Enstiti nasyonal franse pou sante ak rechèch medikal-Ajans nasyonal franse pou rechèch sou SIDA ak epatit viral (Inserm-ANRS)|Bristol-Myers Squibb | Ko-enfeksyon HCV-VIH | Desanm 2012 | Faz 2 |
| NCT02282709 | Fondasyon pou rechèch nan fwa | Epatit C kwonik | Fevriye 2014 | Faz 3 |
| NCT02032888 | Bristol-Myers Squibb | Epatit C | Fevriye 2014 | Faz 3 |
| NCT03247296 | Inivèsite MTI | Epatit C | 28 fevriye 2017 |
|
| NCT01389323 | Bristol-Myers Squibb | Epatit C | Septanm 2011 | Faz 3 |
| NCT02556086 | Bristol-Myers Squibb | Epatit C | Desanm 2015 | Faz 2 |
| NCT01741545 | Bristol-Myers Squibb | Viris Epatit C | 31 mas 2013 | Faz 3 |
| NCT01866930 | Bristol-Myers Squibb | Enfeksyon kwonik epatit C | 11 jiyè 2013 | Faz 3 |
| NCT02268864 | Janssen-Cilag International NV | Epatit C, kwonik | Janvye 2015 | Faz 2 |
| NCT01797848 | Bristol-Myers Squibb | Epatit C | jen 2014 | Faz 3 |
| NCT03166280 | Eman Sayed Hassan Abd Allah|Assiut University | Epatit C | jen 2017 |
|
| NCT02159352 | Bristol-Myers Squibb | Epatit C | jen 2014 | Faz 1 |
| NCT01125189 | Bristol-Myers Squibb | Viris Epatit C | Jiyè 2010 | Faz 2 |
| NCT03748745 | Nanjing Sanhome famasetik, co, Ltd. | Entèaksyon Dwòg | 19 novanm 2018 | Faz 1 |
| NCT01012895 | Bristol-Myers Squibb | Epatit C kwonik | Desanm 2009 | Faz 2 |
| NCT02565888 | Inivèsite Radboud | Epatit C|VIH | Novanm 2015 | Faz 1 |
| NCT02555943 | Sant rechèch limanite ak sante|Beijing 302 Hospital|Nanfang Hospital nan Southern Medical University | Enfeksyon Epatit C kwonik|Koenfeksyon HBV|Reaktivasyon Epatit B | Fevriye 2015 | Faz 2| Faz 3 |
| NCT02304159 | Tarek I. Hassanein, MD, FACP, FAG, AGAF|Southern California Research Center | Epatit C | Siwoz | Janvye 2015 | Faz 4 |
| NCT02580474 | Myeong Jun Song|Bristol-Myers Squibb|Soonchunhyang University Hospital|Dankook University|Chungnam National University Hospital|Konyang University Hospital|Eulji University Hospital|Saint Vincent´s Hospital, Kore di|Konkuk University Hospital|Cheongju St. Mary´s Hospital, Cheongju , Kore|Lopital Severance|Kore di Inivèsite Guro Hospital|Eulji General Hospital|The Catholic University of Korea | Epatit C | Fevriye 2016 | Faz 4 |
| NCT02104843 | Bristol-Myers Squibb | Epatit C | Avril 2014 | Faz 1 |
| NCT01428063 | Bristol-Myers Squibb | Enfeksyon Viris Epatit C | Septanm 2011 | Faz 2 |
| NCT02123654 | Bristol-Myers Squibb | Enfeksyon Viris Epatit C | Avril 2014 | Faz 3 |
| NCT02565862 | Inivèsite Radboud | Epatit C|Dyabèt melitu|Rezistans ensilin | Janvye 2016 | Faz 1 |
| NCT04211844 | Inivèsite Ain Shams | Epatit C kwonik | 1ye oktòb 2019 |
|
| NCT00874770 | Bristol-Myers Squibb | Enfeksyon epatit C | jen 2009 | Faz 2 |
| NCT03883698 | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Ensifizans ren, Kwonik|Epatit C | 15 mas 2019 | Faz 3 |
| NCT01448044 | Bristol-Myers Squibb | Epatit C | Desanm 2011 | Faz 3 |
| NCT01359644 | Bristol-Myers Squibb|Pharmasset | Epatit C kwonik | jen 2011 | Faz 2 |
| NCT01842451 | Vertex Pharmaceuticals Incorporated | Epatit C kwonik|CHC|HCV|Epatit C | jen 2013 | Faz 2 |
| NCT02762448 | Lopital Minisipal Tainan | Epatit c | Jiyè 2016 |
|
| NCT02473211 | Sant rechèch limanite ak sante|Beijing 302 Lopital | Enfeksyon kwonik epatit C | Janvye 2015 | Faz 2| Faz 3 |
| NCT01455090 | Bristol-Myers Squibb | Epatit C kwonik | 30 novanm 2011 | Faz 2 |
| NCT03490097 | Inivèsite Ain Shams | Epatit kwonik c|Sendwòm metabolik | 1ye desanm 2017 | Faz 2| Faz 3 |
| NCT01170962 | Bristol-Myers Squibb | Viris Epatit C | Out 2010 | Faz 2 |
| NCT02333292 | Hospital Universitario Valme|Hospital del SAS de Jerez|Hospital General Universitario Elche|Hospital La Línea de la Concepción|Complexo Hospitalario Universitario de A Coruña|Hospital de Figueres|Hospital Universitario Puerto Real|Hospital Universitario Virgen de la Victoria|Hospital Universitario de Canarias| Hospital General Universitario de Alicante|Hospital Universitario Araba|Hospital Royo Vilanova|Hospital Universitario de Burgos|Complejo Hospitalario Universitario de Huelva|Hospital Universitario Reina Sofia de Cordoba|Hospital Universitario Virgen Macarena|Complexo Hospitalario Universitario de Vigo|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Clinico Universitario San Cecilio|Hospital Universitario La Fe|Hospital General Universitario de Valencia|Hospital Universitario Infanta Leonor|Hospital Universitario de Gran Canaria|Hospital General Universitario Santa Lucía|Centro Penitenciario Alicante 1|Hospital Regional Universitario Carlos Haya|Hospital Virgen de la Luz|Lopital Jeneral Universitario de Castellón|Lopital Parc Taulí, Sabadell | Enfeksyon kwonik epatit C | Desanm 2014 |
|
| NCT03200184 | Teheran University of Medical Sciences | Epatit C | 1ye septanm 2016 | Faz 4 |
| NCT03188276 | Twazyèm Lopital Afilye, Inivèsite Sun Yat-Sen | Epatit C kwonik | 1ye fevriye 2016 | Faz bonè 1 |
| NCT01830205 | Bristol-Myers Squibb | Epatit C | Septanm 2012 | Faz 1 |
Pwopozisyon18Pwojè Evalyasyon Konsistans Kalite ki te apwouve4, epi6pwojè yo anba apwobasyon.
Sistèm avanse jesyon kalite entènasyonal te mete yon fondasyon solid pou lavant yo.
Sipèvizyon kalite kouri atravè tout sik lavi pwodwi a pou asire bon jan kalite a ak efè ki ka geri ou.
Ekip Pwofesyonèl Afè Regilasyon sipòte demann kalite yo pandan aplikasyon an ak enskripsyon an.
Kore di Countec boutèy anbalaj liy
Taiwan CVC boutèy anbalaj liy
Itali CAM Board Packaging Liy
Alman Fette Compacting machin
Japon Viswill tablèt detektè
Sal kontwòl DCS
Koperasyon entènasyonal
Koperasyon domestik
Ekri mesaj ou a isit la epi voye li ba nou
